|
covid-19 |
56 |
|
covid-19 vaccine |
39 |
|
chinese |
37 |
|
sars-cov-2 |
33 |
|
bnt162b2 |
29 |
|
coronavac |
29 |
|
health-related quality of life |
29 |
|
quality of life |
29 |
|
vaccine safety |
29 |
|
covid-19 vaccines |
27 |
|
primary care |
24 |
|
reliability |
21 |
|
validity |
21 |
|
diabetes mellitus |
19 |
|
low-income families |
19 |
|
responsiveness |
19 |
|
type 2 diabetes mellitus |
19 |
|
cancer |
18 |
|
inactivated vaccine |
18 |
|
self-controlled case series |
18 |
|
colorectal cancer |
17 |
|
diabetes |
17 |
|
vaccination |
17 |
|
stroke |
16 |
|
microvascular complications |
15 |
|
sf-12 |
15 |
|
vaccine effectiveness |
15 |
|
hypertension |
14 |
|
pre-diabetes |
14 |
|
safety |
14 |
|
antivirals |
13 |
|
atrial fibrillation |
13 |
|
cardiovascular complications |
13 |
|
cost |
13 |
|
ischemic stroke |
13 |
|
mortality |
13 |
|
patient-reported outcomes |
13 |
|
child health |
12 |
|
cost-effectiveness |
12 |
|
epidemiology |
12 |
|
innate immunity |
12 |
|
quality of care |
12 |
|
tuberculosis |
12 |
|
type 2 diabetes |
12 |
|
hrqol |
11 |
|
omicron |
11 |
|
psychometrics |
11 |
|
risk stratification |
11 |
|
adverse events |
10 |
|
autoimmune disorders |
10 |
|
bidirectional relationship |
10 |
|
cohort study |
10 |
|
delirium |
10 |
|
dementia |
10 |
|
health empowerment |
10 |
|
incident cvd |
10 |
|
long covid |
10 |
|
major adverse cardiovascular events |
10 |
|
mental health |
10 |
|
metformin |
10 |
|
parental stress |
10 |
|
pasc |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
sex difference |
10 |
|
smoking cessation |
10 |
|
adverse events of special interest (aesi) |
9 |
|
anchor |
9 |
|
fact-c |
9 |
|
heart failure |
9 |
|
hong kong |
9 |
|
infection |
9 |
|
molnupiravir |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
nomogram |
9 |
|
patient-centered care |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
physical activity |
9 |
|
sensitivity |
9 |
|
vaccine |
9 |
|
validation |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
adolescent idiopathic scoliosis |
8 |
|
adolescents |
8 |
|
adverse events of special interest |
8 |
|
cardiovascular disease |
8 |
|
children |
8 |
|
ckd |
8 |
|
direct medical cost |
8 |
|
economic burden |
8 |
|
ehr |
8 |
|
emulated trial |
8 |
|
eq-5d-5l |
8 |
|
family doctor |
8 |
|
management programme |
8 |
|
mrna vaccine |
8 |
|
myocarditis |
8 |
|
pediatric population |
8 |
|
pericarditis |
8 |
|
primary health care |
8 |
|
psychometric properties |
8 |
|
risk assessment |
8 |
|
screen time |
8 |
|
service utilization |
8 |
|
sleep duration |
8 |
|
thyroidectomy |
8 |
|
analgesia |
7 |
|
aspirin |
7 |
|
child behaviour |
7 |
|
colorectal neoplasm |
7 |
|
cost-of-illness |
7 |
|
dialysis |
7 |
|
early detection |
7 |
|
early onset scoliosis |
7 |
|
early onset scoliosis-24 questionnaire |
7 |
|
eosq-24 |
7 |
|
eq-5d |
7 |
|
family well-being |
7 |
|
general diabetes |
7 |
|
health care service provider |
7 |
|
health economic analysis |
7 |
|
health literacy |
7 |
|
health preference |
7 |
|
health utility |
7 |
|
hospitalisation |
7 |
|
information sharing |
7 |
|
intimate partner abuse |
7 |
|
lifestyle |
7 |
|
mediation |
7 |
|
mental disorders |
7 |
|
mobile apps |
7 |
|
morphine consumption |
7 |
|
myocardial infarction |
7 |
|
patient enablement |
7 |
|
patient-reported outcome |
7 |
|
placebo |
7 |
|
prediabetes |
7 |
|
prediabetic state |
7 |
|
preventive measures |
7 |
|
public health |
7 |
|
quality in health care |
7 |
|
randomized controlled trial |
7 |
|
rct |
7 |
|
risk factors |
7 |
|
sf-6d |
7 |
|
spa |
7 |
|
spondyloarthritis |
7 |
|
adolescent development |
6 |
|
automated |
6 |
|
cardiovascular health |
6 |
|
child behavior |
6 |
|
child maltreatment |
6 |
|
confirmatory factor analysis |
6 |
|
end-stage renal disease |
6 |
|
family breakfast |
6 |
|
family dinner |
6 |
|
family functioning |
6 |
|
family meal |
6 |
|
glucagon-like peptide-1 receptor agonists |
6 |
|
health disparities |
6 |
|
income instability |
6 |
|
influenza virus |
6 |
|
information technology |
6 |
|
insulin |
6 |
|
job loss |
6 |
|
low income |
6 |
|
measurement invariance |
6 |
|
medical sciences |
6 |
|
mode of administration |
6 |
|
multidisciplinary |
6 |
|
musculoskeletal disorders |
6 |
|
nasopharyngeal |
6 |
|
nocturnal home haemodialysis |
6 |
|
parenting |
6 |
|
point-of-care testing |
6 |
|
prevention |
6 |
|
radioactive iodine |
6 |
|
respiratory syncytial virus |
6 |
|
risk algorithm |
6 |
|
risk prediction |
6 |
|
saliva |
6 |
|
undiagnosed diabetes |
6 |
|
volume–outcome |
6 |
|
volume–quality |
6 |
|
antibiotics |
5 |
|
antibody |
5 |
|
booster |
5 |
|
canagliflozin |
5 |
|
cellular phone |
5 |
|
chatting |
5 |
|
chinese medicine;multi-centre |
5 |
|
chronic disease |
5 |
|
community centre |
5 |
|
community smoker |
5 |
|
competing risks |
5 |
|
corticosteroids |
5 |
|
costing analysis |
5 |
|
dapagliflozin |
5 |
|
database research |
5 |
|
drivers |
5 |
|
drug repurposing |
5 |
|
economic evaluation |
5 |
|
end stage renal disease |
5 |
|
endocrinology |
5 |
|
end‐stage renal disease |
5 |
|
eq-5d-5 l |
5 |
|
fact-p |
5 |
|
general population |
5 |
|
group discussion |
5 |
|
haemodialysis |
5 |
|
health related quality of life |
5 |
|
healthcare costs |
5 |
|
heart disease |
5 |
|
hong kong chinese population |
5 |
|
hospital |
5 |
|
hybrid immunity |
5 |
|
instant messaging |
5 |
|
instrument |
5 |
|
interferons |
5 |
|
intervention |
5 |
|
magnetically controlled growing rod |
5 |
|
mapping |
5 |
|
mcgr |
5 |
|
multi-disciplinary |
5 |
|
multidisciplinary-risk-assessment-and-management-programme |
5 |
|
non-communicable disease |
5 |
|
obesity |
5 |
|
patient‐reported outcome |
5 |
|
physiology |
5 |
|
population norm |
5 |
|
population-based cohort |
5 |
|
predictors |
5 |
|
preventive medicine |
5 |
|
prognosis |
5 |
|
prostate cancer |
5 |
|
recurrence |
5 |
|
relapse prevention |
5 |
|
self-management |
5 |
|
sf-12v2 |
5 |
|
short-message service |
5 |
|
sodium-glucose co-transporter 2 inhibitor |
5 |
|
structured education |
5 |
|
survival |
5 |
|
systematic review |
5 |
|
t cell |
5 |
|
temporal trend |
5 |
|
text messaging |
5 |
|
tgr |
5 |
|
thiazolidinediones |
5 |
|
thypro-39 |
5 |
|
traditional growing rod |
5 |
|
treatment |
5 |
|
unintentional injury |
5 |
|
acute liver injury |
4 |
|
adult |
4 |
|
adults |
4 |
|
anti-diabetic drug |
4 |
|
antithyroid drugs |
4 |
|
asian continental ancestry group |
4 |
|
assessment |
4 |
|
automobile driving |
4 |
|
bariatric surgery |
4 |
|
bodily pain |
4 |
|
cardiovascular disease risk |
4 |
|
cardiovascular diseases - epidemiology |
4 |
|
cardiovascular risk factors |
4 |
|
case series |
4 |
|
cd26 |
4 |
|
clinical audit |
4 |
|
clinical consultation |
4 |
|
colonoscopy |
4 |
|
communication |
4 |
|
cost‐effectiveness |
4 |
|
count data |
4 |
|
diabetes complication |
4 |
|
diabetes mellitus - epidemiology |
4 |
|
diabetes mellitus, type 2 |
4 |
|
dipeptidyl-peptidase iv inhibitors |
4 |
|
dpp4 |
4 |
|
dpp4-inhibitor |
4 |
|
dpp4i |
4 |
|
effectiveness |
4 |
|
emergency services |
4 |
|
empathy |
4 |
|
fecal occult blood testing |
4 |
|
female |
4 |
|
fractures, bone |
4 |
|
gliptin |
4 |
|
good hrqol |
4 |
|
graves’ disease |
4 |
|
health enablement |
4 |
|
health utilization |
4 |
|
home blood pressure monitoring |
4 |
|
hong kong - epidemiology |
4 |
|
hospitalization |
4 |
|
hrqol data |
4 |
|
hrqol outcome |
4 |
|
hrqol score |
4 |
|
humans |
4 |
|
hyperinflammatory syndrome |
4 |
|
idiopathic scoliosis |
4 |
|
in-hospital death |
4 |
|
influenza vaccination |
4 |
|
insulin therapy |
4 |
|
intimate partner violence |
4 |
|
macrovascular disease |
4 |
|
male |
4 |
|
mass screening |
4 |
|
measurement |
4 |
|
medical student |
4 |
|
metabolic syndrome |
4 |
|
metabolic syndrome x - epidemiology |
4 |
|
micro-costing |
4 |
|
microvascular disease |
4 |
|
middle aged |
4 |
|
model recalibration |
4 |
|
multi-morbidity |
4 |
|
multidisciplinary intervention |
4 |
|
nirmatrelvir/ritonavir |
4 |
|
osteoporosis |
4 |
|
papillary thyroid carcinoma |
4 |
|
patient education |
4 |
|
patient-centred care |
4 |
|
peritoneal dialysis first |
4 |
|
person-centered primary care |
4 |
|
population based cohort |
4 |
|
preference |
4 |
|
priming |
4 |
|
professional drivers |
4 |
|
psychometric |
4 |
|
quality in healthcare |
4 |
|
quality-of-life |
4 |
|
questionnaire |
4 |
|
ramp-dm |
4 |
|
recurrent laryngeal nerve |
4 |
|
risk estimation |
4 |
|
risk judgment |
4 |
|
risk management |
4 |
|
risk prediction model |
4 |
|
robotic thyroidectomy |
4 |
|
self-care enablement |
4 |
|
self-management education |
4 |
|
sglt2 inhibitor |
4 |
|
socio-economics factors |
4 |
|
sodium-glucose cotransporter 2 inhibitors |
4 |
|
sodium-glucose transporter 2 inhibitors |
4 |
|
thyroid cancer |
4 |
|
thyroid nodule |
4 |
|
total thyroidectomy |
4 |
|
type 2 diabetes, structured education |
4 |
|
undergraduate |
4 |
|
undiagnosed dm |
4 |
|
urology |
4 |
|
viral clearance |
4 |
|
5-level eq-5d |
3 |
|
acoustic analysis |
3 |
|
addqol-19 |
3 |
|
agreement |
3 |
|
antiviral activity |
3 |
|
back-specific |
3 |
|
bbq |
3 |
|
benign prostatic hyperplasia |
3 |
|
bmi |
3 |
|
bracing |
3 |
|
cardiovascular diseases |
3 |
|
central lymph nodes |
3 |
|
central neck dissection |
3 |
|
cervical myelopathy |
3 |
|
cervical spondylotic myelopathy |
3 |
|
clinical improvement |
3 |
|
cosmin |
3 |
|
cost-effectiveness analysis (ce) |
3 |
|
counseling |
3 |
|
curfew |
3 |
|
decision making |
3 |
|
decompression |
3 |
|
diabetes care |
3 |
|
diabetes remission |
3 |
|
diagnosis |
3 |
|
direct medical costs |
3 |
|
discrete choice experiment |
3 |
|
dysphonia |
3 |
|
endoscopic |
3 |
|
endoscopic thyroidectomy |
3 |
|
eortc qlq-c30 |
3 |
|
eq-5d-3l-y |
3 |
|
eq-5d-y |
3 |
|
euroqol 5-dimension 5-level |
3 |
|
fabq |
3 |
|
feasibility |
3 |
|
flat feet |
3 |
|
focussed ultrasound |
3 |
|
fracture |
3 |
|
gastrectomy |
3 |
|
gastric bypass |
3 |
|
hba1c |
3 |
|
healthcare utilisation |
3 |
|
healthcare utilization |
3 |
|
hpv |
3 |
|
hypoparathyroidism |
3 |
|
igt |
3 |
|
impaired fasting glucose |
3 |
|
incremental cost-effectiveness ratio threshold |
3 |
|
intra-operative neuro-monitoring |
3 |
|
ipss |
3 |
|
joacmeq |
3 |
|
lockdown |
3 |
|
low back pain |
3 |
|
lumbar spinal stenosis (lss) |
3 |
|
measurement property |
3 |
|
medical education |
3 |
|
microsurgery |
3 |
|
national containment |
3 |
|
nerve monitoring |
3 |
|
nodule shrinkage |
3 |
|
non-laboratory-based |
3 |
|
non-robotic thyroidectomy |
3 |
|
norm |
3 |
|
normoglycaemia |
3 |
|
novel predictor |
3 |
|
ogtt |
3 |
|
opioid |
3 |
|
paediatric quality of life inventory |
3 |
|
persistent opioid use |
3 |
|
population‐based study |
3 |
|
postoperative outcomes |
3 |
|
prediction model |
3 |
|
preference-based |
3 |
|
preference-based scores |
3 |
|
proxy |
3 |
|
quality-adjusted life-years |
3 |
|
re-operation |
3 |
|
recurrent laryngeal nerve palsy |
3 |
|
refined scoliosis research society 22-item questionnaire |
3 |
|
regression |
3 |
|
remdesivir |
3 |
|
risk prediction tools |
3 |
|
scoliosis research society 22-item |
3 |
|
screening |
3 |
|
severe hypoglycaemia |
3 |
|
short messaging services |
3 |
|
short-form 6-dimension |
3 |
|
stay-at-home |
3 |
|
student attitudes |
3 |
|
thermal ablation |
3 |
|
thypro |
3 |
|
thyroglobulin |
3 |
|
thyroid |
3 |
|
thyroid disease |
3 |
|
undergraduate medical curriculum |
3 |
|
utility |
3 |
|
voice |
3 |
|
willingness to pay |
3 |
|
youth |
3 |
|
attitude |
2 |
|
blood pressure monitoring |
2 |
|
cancer death |
2 |
|
cancer incidence |
2 |
|
chronic hepatitis b |
2 |
|
cluster‐randomized controlled trial |
2 |
|
colon (anatomy) - cancer - patients - china - hong kong |
2 |
|
comparative study |
2 |
|
cost effectiveness |
2 |
|
cost-effectiveness analysis |
2 |
|
costs |
2 |
|
count data models |
2 |
|
cubic spline |
2 |
|
daytime napping |
2 |
|
digital intervention |
2 |
|
discriminative power |
2 |
|
disease-specific death |
2 |
|
fear |
2 |
|
fine-needle aspiration |
2 |
|
fnac |
2 |
|
group education |
2 |
|
harm reduction |
2 |
|
hiv prevention |
2 |
|
inferior retractor plication |
2 |
|
innovative model |
2 |
|
involutional entropion |
2 |
|
lateral tarsal strip |
2 |
|
lid laxity |
2 |
|
mapping models |
2 |
|
meta-analysis |
2 |
|
non-invasive variables |
2 |
|
normative |
2 |
|
normative value |
2 |
|
pentagonal resection |
2 |
|
predicting recurrence |
2 |
|
prostitution |
2 |
|
psychological health |
2 |
|
qalys |
2 |
|
quality of life - china - hong kong |
2 |
|
questionnaires |
2 |
|
rectum - cancer - patients - china - hong kong |
2 |
|
reduced egfr |
2 |
|
risk behaviors |
2 |
|
sex education |
2 |
|
sexual health |
2 |
|
sexually transmitted infection |
2 |
|
sf-36 |
2 |
|
social media |
2 |
|
sodium glucose cotransporter-2 inhibitors |
2 |
|
sti |
2 |
|
thyroid carcinoma |
2 |
|
thyroid nodules |
2 |
|
web-based intervention |
2 |
|
working population |
2 |
|
young adult |
2 |
|
zero-inflated models |
2 |
|
adrenal cortex adenoma |
1 |
|
adrenal hyperplasia |
1 |
|
adrenalectomy |
1 |
|
advanced non-small cell lung cancer |
1 |
|
aged |
1 |
|
airflow obstruction |
1 |
|
aldosterone |
1 |
|
anaplastic lymphoma kinase-positive |
1 |
|
attendance rate |
1 |
|
bckq |
1 |
|
bcss |
1 |
|
cardiology |
1 |
|
cavity quantum electrodynamics |
1 |
|
ceritinib; cost-effectiveness |
1 |
|
chronic obstructive pulmonary disease |
1 |
|
colour cards |
1 |
|
comorbidities |
1 |
|
copd |
1 |
|
coronary heart disease |
1 |
|
disease progression |
1 |
|
early diagnosis |
1 |
|
education |
1 |
|
eq-5d-3l |
1 |
|
erectile dysfunction |
1 |
|
family medicine |
1 |
|
general practice |
1 |
|
health-related quality of life (hrqol) |
1 |
|
hyperglycemia |
1 |
|
interlayer exciton |
1 |
|
kdqol-36 |
1 |
|
knowledge |
1 |
|
lower gastrointestinal bleeding |
1 |
|
multidisciplinary services |
1 |
|
mycoplasma infections |
1 |
|
nanoresonator |
1 |
|
obstructive sleep apnoea |
1 |
|
per-rectal bleeding |
1 |
|
peripheral blood indices |
1 |
|
polymerase chain reaction |
1 |
|
prevalence |
1 |
|
respiratory symptoms |
1 |
|
sarcoma |
1 |
|
sexually transmitted diseases |
1 |
|
short message service (sms) |
1 |
|
sigmoidoscopy |
1 |
|
smokers |
1 |
|
smoking |
1 |
|
spirometry |
1 |
|
ureaplasma infections |
1 |
|
urethritis |
1 |
|
動機性訪談 |
1 |
|
基層保健 |
1 |
|
藥物相關性障礙 |
1 |
